View in EDS

Macrophage Membrane-Coated Nanocarriers in Myocardial Infarction: A Paradigm Shift in Targeted Cardiac Therapy

Saved in:
Bibliographic Details
Title: Macrophage Membrane-Coated Nanocarriers in Myocardial Infarction: A Paradigm Shift in Targeted Cardiac Therapy
Authors: Wang L, Wang K, Zheng H
Source: International Journal of Nanomedicine, Vol 20, Iss Issue 1, Pp 13499-13525 (2025)
Publisher Information: Dove Medical Press, 2025.
Publication Year: 2025
Collection: LCC:Medicine (General)
Subject Terms: Macrophage membrane-coated nanocarriers, Myocardial infarction therapy, Biomimetic drug delivery systems, Cardiac tissue regeneration, Immune modulation in heart repair, Targeted nanomedicine, Medicine (General), R5-920
Description: Liping Wang,1 Kaili Wang,2 Hongjian Zheng2 1Department of Cardiology, Chun’an First People’s Hospital, Hangzhou, Zhejiang Province, 311700, People’s Republic of China; 2Nursing Department, Chun’an First People’s Hospital, Hangzhou, Zhejiang Province, 311700, People’s Republic of ChinaCorrespondence: Hongjian Zheng, Nursing Department, Chun’an First People’s Hospital, No. 1869 Huanhubei Road, Hangzhou, Zhejiang Province, 311700, People’s Republic of China, Email Zhenghj1245@163.comAbstract: Myocardial infarction remains a major contributor to global morbidity and mortality, with current therapeutic strategies often falling short in addressing post-infarction inflammation, fibrotic remodeling, and suboptimal drug localization. Macrophages are key modulators of the cardiac immune microenvironment, play a dual role in tissue damage and repair by polarizing into distinct inflammatory and reparative phenotypes. Recent advancements in biomimetic nanotechnology have facilitated the development of macrophage membrane-coated nanocarrier engineered systems that replicate the functional surface characteristics of native macrophages. These nanocarriers offer enhanced therapeutic precision by enabling immune evasion, targeted delivery to infarcted myocardium, and sustained release of bioactive agents. Their prolonged systemic circulation further augments therapeutic efficacy. Current clinical strategies remain insufficient in preventing long-term complications such as adverse cardiac remodeling and the development of heart failure, highlighting a critical need for targeted and effective post-MI therapies. This review comprehensively evaluates the biological role of macrophages in the context of myocardial infarction and highlights current innovations in the fabrication and functional optimization of macrophage membrane-coated nanocarriers. We further discuss their mechanisms of action, therapeutic benefits demonstrated in preclinical models, and their prospective integration into regenerative treatment paradigms. Critical challenges, including regulatory approval, manufacturing scalability, and clinical translation, are also discussed. These nanocarriers represent a promising frontier in myocardial infarction therapy, offering targeted, biocompatible, and immune-responsive drug delivery platforms.Keywords: macrophage membrane-coated nanocarriers, myocardial infarction therapy, biomimetic drug delivery systems, cardiac tissue regeneration, immune modulation in heart repair, targeted nanomedicine, translational nanotechnology
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1178-2013
Relation: https://www.dovepress.com/macrophage-membrane-coated-nanocarriers-in-myocardial-infarction-a-par-peer-reviewed-fulltext-article-IJN; https://doaj.org/toc/1178-2013
Access URL: https://doaj.org/article/0dd23f5a4e874b049c65b9ce3b1130e8
Accession Number: edsdoj.0dd23f5a4e874b049c65b9ce3b1130e8
Database: Directory of Open Access Journals
Description
Abstract:Liping Wang,1 Kaili Wang,2 Hongjian Zheng2 1Department of Cardiology, Chun’an First People’s Hospital, Hangzhou, Zhejiang Province, 311700, People’s Republic of China; 2Nursing Department, Chun’an First People’s Hospital, Hangzhou, Zhejiang Province, 311700, People’s Republic of ChinaCorrespondence: Hongjian Zheng, Nursing Department, Chun’an First People’s Hospital, No. 1869 Huanhubei Road, Hangzhou, Zhejiang Province, 311700, People’s Republic of China, Email Zhenghj1245@163.comAbstract: Myocardial infarction remains a major contributor to global morbidity and mortality, with current therapeutic strategies often falling short in addressing post-infarction inflammation, fibrotic remodeling, and suboptimal drug localization. Macrophages are key modulators of the cardiac immune microenvironment, play a dual role in tissue damage and repair by polarizing into distinct inflammatory and reparative phenotypes. Recent advancements in biomimetic nanotechnology have facilitated the development of macrophage membrane-coated nanocarrier engineered systems that replicate the functional surface characteristics of native macrophages. These nanocarriers offer enhanced therapeutic precision by enabling immune evasion, targeted delivery to infarcted myocardium, and sustained release of bioactive agents. Their prolonged systemic circulation further augments therapeutic efficacy. Current clinical strategies remain insufficient in preventing long-term complications such as adverse cardiac remodeling and the development of heart failure, highlighting a critical need for targeted and effective post-MI therapies. This review comprehensively evaluates the biological role of macrophages in the context of myocardial infarction and highlights current innovations in the fabrication and functional optimization of macrophage membrane-coated nanocarriers. We further discuss their mechanisms of action, therapeutic benefits demonstrated in preclinical models, and their prospective integration into regenerative treatment paradigms. Critical challenges, including regulatory approval, manufacturing scalability, and clinical translation, are also discussed. These nanocarriers represent a promising frontier in myocardial infarction therapy, offering targeted, biocompatible, and immune-responsive drug delivery platforms.Keywords: macrophage membrane-coated nanocarriers, myocardial infarction therapy, biomimetic drug delivery systems, cardiac tissue regeneration, immune modulation in heart repair, targeted nanomedicine, translational nanotechnology
ISSN:11782013